(-)-DHMEQ is a potent, selective, and irreversible NF-κB inhibitor that covalently binds to cysteine residues; it inhibits nuclear translocation of NF-κB and exhibits anti-inflammatory and anticancer activities; it significantly reduces viability of various cancer cell lines in a dose- and time-dependent manner; induces apoptosis in MT-1 and TL-Om1 cells; down-regulates anti-apoptotic and cell cycle-related proteins (Bcl-xL, Bcl-2, c-myc, cyclin D1, Rb, p53) and up-regulates pro-apoptotic caspases (-3, -8, -9); causes G0/G1 cell cycle arrest; inhibits DNA-binding and nuclear import of RelB; promotes RelB instability; and significantly improves survival in SCID mice bearing MT-2 tumor xenografts.